Diabetic Maximum Strength Siltussin DM DAS-Na

Product NDC
54838-140
11-digit product format
548380140
Labeler code
54838
Product ID
54838-140_c723bfab-3297-4b37-82ec-9bbd11e124b8
Type
HUMAN OTC DRUG
Nonproprietary name
Guaifenesin and Dextromethorphan Hydrobromide
Dosage form
LIQUID
Route
ORAL
Labeler
Lannett Company, Inc.
Application
part341
Marketing category
OTC MONOGRAPH FINAL
Marketing start
2005-11-05
Marketing end
0000-00-00
Substance
GUAIFENESIN; DEXTROMETHORPHAN HYDROBROMIDE
Active strength
200 mg/5mL; mg/5mL
NDC exclude flag
No
Listing certified through
2020-12-31
Current FDA listing
Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 2 matching rows.

Dataset, Scope, Product NDC table
DatasetScopeProduct NDCPackage NDCCodeStatusReporting periodSource date
excluded productproduct54838-140DDiscontinued by firm2026-10-05
excluded packagepackage54838-14054838-140-40DDiscontinued by firm2026-10-05

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 1 · 24 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source dateDatasetScopePackage NDCSnapshotSource SHA-256
2025-12-14 17:58 UTC · source 2025-12-05excluded productproductd630ba8d3edf…732f749b63fb…
2025-12-14 17:58 UTC · source 2025-12-05excluded packagepackage54838-140-40d630ba8d3edf…732f749b63fb…
2025-08-27 00:01 UTC · source 2025-08-26excluded productproductf5e01cc5f278…a2eaf40c39c3…
2025-08-27 00:01 UTC · source 2025-08-26excluded packagepackage54838-140-40f5e01cc5f278…a2eaf40c39c3…
2025-04-01 02:39 UTC · source 2025-03-31excluded productproduct2ef7874e63bc…57b86245f4fa…
2025-04-01 02:39 UTC · source 2025-03-31excluded packagepackage54838-140-402ef7874e63bc…57b86245f4fa…
2025-03-28 20:22 UTC · source 2025-03-28excluded productproducta1b67e2a42f9…c4cf2c586c0d…
2025-03-28 20:22 UTC · source 2025-03-28excluded packagepackage54838-140-40a1b67e2a42f9…c4cf2c586c0d…
2025-03-22 03:12 UTC · source 2025-03-21excluded productproductcfe11265f3b6…090c488252e2…
2025-03-22 03:12 UTC · source 2025-03-21excluded packagepackage54838-140-40cfe11265f3b6…090c488252e2…
2025-03-10 12:48 UTC · source 2025-03-10excluded productproductcdf11ea48f46…ba0047e9e063…
2025-03-10 12:48 UTC · source 2025-03-10excluded packagepackage54838-140-40cdf11ea48f46…ba0047e9e063…
2025-02-02 03:52 UTC · source 2025-01-31excluded productproduct302b2466d912…e7b80fea0513…
2025-02-02 03:52 UTC · source 2025-01-31excluded packagepackage54838-140-40302b2466d912…e7b80fea0513…
2025-01-20 13:05 UTC · source 2025-01-20excluded productproducted331223b511…672a5bd82f5f…
2025-01-20 13:05 UTC · source 2025-01-20excluded packagepackage54838-140-40ed331223b511…672a5bd82f5f…
2025-01-11 03:41 UTC · source 2025-01-10excluded productproduct0efc9e666f02…f202fb6c5f17…
2025-01-11 03:41 UTC · source 2025-01-10excluded packagepackage54838-140-400efc9e666f02…f202fb6c5f17…
2024-11-09 02:27 UTC · source 2024-11-08excluded productproductad56d346431e…cc804d4bbf1e…
2024-11-09 02:27 UTC · source 2024-11-08excluded packagepackage54838-140-40ad56d346431e…cc804d4bbf1e…
2024-10-04 04:10 UTC · source 2024-10-03excluded productproduct367a005e9d99…383a685ebd0f…
2024-10-04 04:10 UTC · source 2024-10-03excluded packagepackage54838-140-40367a005e9d99…383a685ebd0f…
2024-07-10 04:00 UTC · source 2024-07-09excluded productproduct557ba5c1ecfa…9c80585c8c6e…
2024-07-10 04:00 UTC · source 2024-07-09excluded packagepackage54838-140-40557ba5c1ecfa…9c80585c8c6e…

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
54838-140-40ML - Milliliter54838-1405e7d4069-422a-4210-8ff8-ac950dc6528e12012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIIDailyMed labelSPL versionUploaded
Dextromethorphan HydrobromideACTIVE INGREDIENT9D2RTI9KYHDIABETIC MAXIMUM STRENGTH SILTUSSIN DM DAS-NA (GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE) LIQUID [SILARX PHARMACEUTICALS, INC]12
GuaifenesinACTIVE INGREDIENT495W7451VQDIABETIC MAXIMUM STRENGTH SILTUSSIN DM DAS-NA (GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE) LIQUID [SILARX PHARMACEUTICALS, INC]12
DextromethorphanACTIVE MOIETY7355X3ROTSDIABETIC MAXIMUM STRENGTH SILTUSSIN DM DAS-NA (GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE) LIQUID [SILARX PHARMACEUTICALS, INC]12
GuaifenesinACTIVE MOIETY495W7451VQDIABETIC MAXIMUM STRENGTH SILTUSSIN DM DAS-NA (GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE) LIQUID [SILARX PHARMACEUTICALS, INC]12
acesulfame potassiumINACTIVE INGREDIENT23OV73Q5G9DIABETIC MAXIMUM STRENGTH SILTUSSIN DM DAS-NA (GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE) LIQUID [SILARX PHARMACEUTICALS, INC]12
anhydrous citric acidINACTIVE INGREDIENTXF417D3PSLDIABETIC MAXIMUM STRENGTH SILTUSSIN DM DAS-NA (GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE) LIQUID [SILARX PHARMACEUTICALS, INC]12
aspartameINACTIVE INGREDIENTZ0H242BBR1DIABETIC MAXIMUM STRENGTH SILTUSSIN DM DAS-NA (GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE) LIQUID [SILARX PHARMACEUTICALS, INC]12
benzoic acidINACTIVE INGREDIENT8SKN0B0MIMDIABETIC MAXIMUM STRENGTH SILTUSSIN DM DAS-NA (GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE) LIQUID [SILARX PHARMACEUTICALS, INC]12
HYPROMELLOSE 2910 (4000 MPA.S)INACTIVE INGREDIENTRN3152OP35DIABETIC MAXIMUM STRENGTH SILTUSSIN DM DAS-NA (GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE) LIQUID [SILARX PHARMACEUTICALS, INC]12
methylparabenINACTIVE INGREDIENTA2I8C7HI9TDIABETIC MAXIMUM STRENGTH SILTUSSIN DM DAS-NA (GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE) LIQUID [SILARX PHARMACEUTICALS, INC]12
propylene glycolINACTIVE INGREDIENT6DC9Q167V3DIABETIC MAXIMUM STRENGTH SILTUSSIN DM DAS-NA (GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE) LIQUID [SILARX PHARMACEUTICALS, INC]12
waterINACTIVE INGREDIENT059QF0KO0RDIABETIC MAXIMUM STRENGTH SILTUSSIN DM DAS-NA (GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE) LIQUID [SILARX PHARMACEUTICALS, INC]12

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionUnitsMarketing startMarketing endSampleExclude flagStatus
54838-140-4054838014040118 mL in 1 BOTTLE, PLASTIC (54838-140-40) 118 ml2005-11-050000-00-00NoNoCurrent